Davisson R L, Bates J N, Johnson A K, Lewis S J
Cardiovascular Center, University of Iowa, Iowa City 52242, USA.
Hypertension. 1996 Sep;28(3):354-60. doi: 10.1161/01.hyp.28.3.354.
In the present study, we examined the possibility that the endothelium-dependent vasodilators acetylcholine and bradykinin release preformed pools of nitric oxide-containing factors. Successive injections of selected doses of acetylcholine (1.18 +/- 0.3 micrograms/kg IV) or bradykinin (5 micrograms/kg IV) caused reproducible hypotensive and vasodilator responses within sympathetically intact and sympathetically denervated hindlimbs of conscious rats. After administration of the nitric oxide synthesis inhibitor N omega-nitro-L-arginine methyl ester (L-NAME, 25 mumol/kg IV), the first injection of acetylcholine or bradykinin produced pronounced depressor and vasodilator responses that, in the case of bradykinin, were greater than those observed before L-NAME administration. However, each successive injection of acetylcholine and bradykinin produced progressively smaller responses, such that the later injections elicited a markedly diminished hypotension and vasodilation. This "use-dependent" loss of endothelium-dependent vasodilation was not due to the diminished vasorelaxant potency of nitric oxide-containing factors because the vasodilator effects of the nitric oxide donor sodium nitroprusside (32 micrograms/kg IV) and the S-nitrosothiol compound S-nitro-socysteine (200 nmol/kg IV) were augmented in the presence of L-NAME. These results suggest that the use-dependent loss of the hemodynamic effects of acetylcholine and bradykinin in L-NAME-treated rats may be due to the release and subsequent depletion of a factor whose synthesis depends on the bioavailability of nitric oxide. Taken together, these results suggest that preformed pools of nitric oxide-containing factors exist within the endothelium of resistance vessels and that endothelium-dependent agonists exert their vasorelaxant effects at least in part by the mobilization of these performed pools.
在本研究中,我们检验了内皮依赖性血管舒张剂乙酰胆碱和缓激肽释放预先形成的含一氧化氮因子池的可能性。在清醒大鼠完整交感神经支配和去交感神经支配的后肢中,连续注射选定剂量的乙酰胆碱(1.18±0.3微克/千克静脉注射)或缓激肽(5微克/千克静脉注射)可引起可重复的降压和血管舒张反应。在给予一氧化氮合成抑制剂Nω-硝基-L-精氨酸甲酯(L-NAME,25微摩尔/千克静脉注射)后,首次注射乙酰胆碱或缓激肽产生明显的降压和血管舒张反应,就缓激肽而言,这些反应大于L-NAME给药前观察到的反应。然而,随后每次注射乙酰胆碱和缓激肽产生的反应逐渐变小,以至于后来的注射引起的低血压和血管舒张明显减弱。这种内皮依赖性血管舒张的“使用依赖性”丧失并非由于含一氧化氮因子的血管舒张效力降低,因为在存在L-NAME的情况下,一氧化氮供体硝普钠(32微克/千克静脉注射)和S-亚硝基硫醇化合物S-亚硝基半胱氨酸(200纳摩尔/千克静脉注射)的血管舒张作用增强。这些结果表明,在L-NAME处理的大鼠中,乙酰胆碱和缓激肽血流动力学效应的使用依赖性丧失可能是由于一种合成依赖于一氧化氮生物利用度的因子的释放和随后的耗竭。综上所述,这些结果表明,在阻力血管内皮中存在预先形成的含一氧化氮因子池,并且内皮依赖性激动剂至少部分地通过动员这些预先形成的池发挥其血管舒张作用。